Zvenyslava Masliak
Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine(UA)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Protein Degradation and Inhibitors
Most-Cited Works
- → Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma(2007)1,455 cited
- → Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study(2011)912 cited
- → Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study(2020)333 cited
- → The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function(2010)130 cited
- → Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study(2018)89 cited
- → Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study(2015)35 cited
- → High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study(2010)31 cited
- → Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma(2023)23 cited
- → Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study(2018)16 cited
- → A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma(2010)13 cited